Temperature Sensitive Polymers

ABSTRACT

The present invention relates to compositions comprising polymers whose solubility characteristics can be changed by incubation and particularly ploy (hydroxyalkyl (meth) acrylamide mono/di-lactate) interpolymers. Another aspect of this invention is the application of such temperature sensitive polymers as release systems of biologically active compounds. The polymers of the present invention comprise monomers, which have modifiable functionality. The functionality of the monomers can for example be modified by the presence of hydrolysable groups. The modification is effected by the incubation, leading to a change of the water solubility characteristics of the polymer. The polymers used in the present invention contain hydrolysable chemical groups. As a result the polymer&#39;s solution characteristics, specifically its lower critical solution temperature (LCST), change upon incubation.

FIELD OF THE INVENTION

The invention relates to compositions comprising polymers whosesolubility characteristics can be changed by incubation. Another aspectof this invention is the application of such temperature sensitivepolymers as release systems of biologically active compounds. In yet afurther aspect, the invention relates to a novel class of polymers withtuneable thermosensitivity, which polymers are biodegradable formingdegradation products that are either endogenous or non-toxic in thehuman or animal system.

The fast developments in the field of molecular biology andbiotechnology have made it possible to produce a large number ofpharmaceutically interesting products in large quantities. For instance,pharmaceutically active peptides and proteins can suitably be used asdrugs in the treatment of life-threatening diseases, e.g. cancer, and ofseveral types of viral, bacterial and parasital diseases; in thetreatment of e.g. diabetes; in vaccines, e.g. for prophylactic aims; foranti-conception purposes, and so on and so forth. Especially thespecialized biological activities of these types of drugs providetremendous advantages over other types of pharmaceutics. Also lowmolecular weight pharmaceuticals, such as cytostatics, antibiotics,etc., can be produced in large amounts.

In addition, it appears that at least for certain classes ofpharmaceutical proteins, such as cytokines which are presently used ine.g. cancer treatments, the therapeutic efficacy is strongly dependenton effective delivery, e.g. intra- or peritumoral. In such cases, theprotein drugs should be directed to the sites where their activity isneeded during a prolonged period of time.

More generally, at present a large number of low molecular weighttherapeutics are becoming available which may have unfavorablebiopharmaceutical characteristics (low bioavailability; low dissolutioncharacteristics; severe side effects; etc. Therefore new solubilizationsystems are urgently needed.

Moreover, low molecular weight drugs, e.g. cytostatica such aspaclitaxel, should be targeted towards specific sites in a body.Suitable drug targeting systems for targeted release are, e.g. micellarstructures for release of low molecular weight drugs.

Hence, there is a need for delivery systems which have the capacity forsustained, controlled and/or targetted release. In the art, deliverysystems comprising soluble polymers have been proposed. Such deliverysystems can be obtained by using such soluble polymers for example inthe form of microparticles in which the drug is encapsulated. Thepolymer can be present throughout each microparticle, with the drugcaptured within the different polymer molecules. Alternatively, thepolymer forms the outer membrane of the microparticle which contains thedrug. However, in vitro or in vivo application of such systems has someinherent drawbacks. First, organic solvents have to be used toencapsulate drugs in the microparticles. Second, acidic products arefrequently formed during degradation, which might result in a loweringof the pH. Both a low pH and organic solvents can affect drug stability,especially if the drug is a protein. Furthermore, it appears to bedifficult to control the drug release from these systems, which can leadto a burst release (see in this respect Van de Weert et al. Proteininstability in polyoactic-co-glycolic acid) microparticles, Pharm Res(2000); 17:1159-1167).

The present inventors have found that the use of temperature sensitivepolymers, and especially those with a lower critical solutiontemperature, has a number of advantages.

Temperature sensitive (or thermosensitive) polymers with a lowercritical solution temperature (LCST) are presently under investigationfor biomedical and pharmaceutical applications. Thermosensitive polymershaving a LCST are remarkable materials, in that below this temperaturesuch polymers are soluble, and above it they precipitate. The lowercritical solution temperature can be defined as the temperature at thepoint of inflection in a graph representing the amount of solids in thesample (for example as measured using light scattering techniques) vs.temperature. Alternatively, the LCST can be defined as the lowesttemperature where precipitated polymer particles are detected (the‘onset’ temperature). An example of a light scattering curve is shown inFIG. 1. Both the temperature at the point of inflection and the onsettemperature are marked. Unless otherwise indicated, in the presentdescription LCST is defined by the onset.

Thermosensitive polymers with LCST are soluble in aqueous solutionsbelow the cloud point (CP), but precipitate above this temperature dueto the dehydration of the polymer chains.

LCST-polymers can be used advantageously as drug release systems,because their preparation can be carried out at a temperature which islower than the temperature at which the release is to be effected, forexample the body temperature. Since the temperature can be kept low,there is little risk of denaturation or degradation of the (protein)drug to be released. Another important advantage of the use ofLCST-polymers in drug release systems is that the loading of the drugdelivery system can be accomplished in an aqueous system, avoiding theuse of toxic organic solvents. In addition, the LCST-polymers can bechosen such that they are degradable and/or can easily be excreted bythe kidneys, once in soluble form.

BACKGROUND OF THE STATE OF THE ART

The use of LCST polymers as controlled release systems is e.g. knownfrom U.S. Pat. No. 5,720,976. In this publication release systems aredisclosed, wherein an active ingredient is encapsulated in liposomes.LCST polymers are grafted to the surface of liposomes. By choosing theratio of respective monomers in the LCST polymers, the LCST value of thepolymers can be adjusted.

Furthermore, WO-A-92/07881 discloses that the solubility ofpolyacrylamide changes as a result of the presence of amide groups,which groups have a buffering effect. This pertains to the solubilityper se, not to the LCST, which is not mentioned in this publication.

Also in EP-A-0 693 508 and in DE-A-4 023 578, it is described that thetemperature sensitivity of certain polymers can be influenced by varyingthe ratio of the comonomers present in these certain polymers.

None of these prior art documents teach or suggest however, that LCSTpolymer systems can be modified, as is done in accordance with thepresent invention in such a way, that the LCST value of the polymerschanges during incubation and as a result of incubation, and by whichthe above mentioned advantages of the present invention can be obtained.

In WO 01/09198, it is disclosed that a temperature sensitive polymer canbe obtained by choosing a monomer that is suitable for the envisagedapplication, e.g. a monomer that forms a pharmaceutically acceptablepolymer. Suitable monomers are the monomers selected from the groupcomprising ethylene glycol, lactic acid, acrylamide, methacrylamide,acrylic acid, and derivates and substituted species thereof. Thesemonomers and/or other monomers are then reacted under suitableconditions to form homopolymers of one of these monomers or copolymers,terpolymers or other polymers of two or more monomers.

In a preferred embodiment of the invention described in WO 01/09198, thechange of solubility characteristics is effected by hydrolysis of agroup, such as a lactate, present on at least one of the monomers thatform the polymer. In case of an in vivo application such a group canadvantageously be an enzymatically or chemically hydrolyzable group. Theester groups are introduced in the polymer by choosing suitable monomersas a starting material. The monomers can be provided with ester groupsby techniques known to the person skilled in the art.

In WO 01/09198 the preferred embodiment is based onpoly(N-isopropylacrylamide) (PNIPAAm), which has its CP (in water)around 32° C. It is the most extensively studied thermosensitive polymerand is used for the design of thermosensitive drug delivery systems suchas polymeric micelles and hydrogels. This polymer has also been used tomodify the surface properties of liposomes. The CP of PNIPAAm can bemodulated by copolymerising with hydrophobic or hydrophilic comonomers:hydrophobic comonomers decrease the CP whereas hydrophilic comonomershave the opposite effect.

The most preferred thermosensitive polymers of WO 01/09198 arethermosensitive copolymers of NIPAAm and N-(2-hydroxypropyl)methacrylamide lactate (poly(NIPAAm-co-HPMAm-lactate)) and their blockcopolymers with poly(ethylene glycol)(poly(NIPAAm-co-HPMAm-lactate)-b-PEG). When >35 mol % HPMAm-lactate wascopolymerised with NIPAAm, these polymers had their CP below bodytemperature, whereas after hydrolysis of the lactate side chain the CPincreased above 37° C. As a result, polymeric micelles formed withpoly(NIPAAm-co-HPMAm-lactate)-b-PEG showed controlled instability atbody temperature.

BRIEF DESCRIPTION OF THE INVENTION

The invention relates to a temperature sensitive polymer having a lowercritical solution temperature that changes during incubation in anaqueous solution or medium, which polymer is a homo or interpolymer of ahydrophobically modified hydroxyalkyl (meth)acrylamide. Thehydrophobical modification may in particular be effected by ahydrophobic unit, bound to the hydroxyalkyl (meth)acrylamide via adegradable bond (such as a lactate ester).

As used herein the term “hydrophobically modified” in a polymeraccording to the invention means that the distribution coefficient P ofthe hydrophobically modified polymer is lower than that of the samepolymer without the modification. P can be determined by mixing anamount of the polymer in a two-phase system of equal amounts of waterand octanol, letting the system phase separate, measuring theequilibrium concentrations of the polymer in the water and the octanoland divide the concentration in water by de concentration in octanol.

Preferably log P is reduced by at least 0.1. More in particularhydrophobic modification results in a reduction of the cloud point ofthe polymer, compared to the unmodified hydroxyalkyl (meth)acrylamide,to a cloud point of 37° C. or less.

Suitable hydrophobic units include lactates, alkyl groups and arylgroups.

The alkyl may be a linear, branched or cyclic alkyl. It may have from 1to 40 carbon atoms, in particular from 2 to 18 carbon atoms. Examples ofalkyl groups include fatty acid ester residues.

Suitable aryl groups include arylgroups having from 4-40 carbon atomes,in particular from 6 to 18 carbon atoms.

The lactate may be a monolactate or an oligolactate. The termoligolactate in particular encompasses oligomers of lactic acidcomprising 2-10 lactic acid residues.

The alkyl in hydroxyalkyl (meth)acrylamide is preferably selected fromthe group consisting of methyl, ethyl, propyl, butyl, pentyl and hexyl.These alkyls include all constitutional isomers of said alkyls (such asthe n-alkyl and the isoalkyl).

A relatively small alkyl, such as methyl or ethyl is in particularconsidered suitable for imparting a relatively low hydrophobicity of thepolymer, and/or relatively high cloud point (CP) (compared to propyl),whereas a relatively large alkyl (such as butyl, pentyl or hexyl) mayhave the opposite effect.

The hydroxy alkyl may be a primary hydroxyl alkyl, a secondary hydroxylalkyl or a tertiary hydroxyl alkyl. A hydrophobically modified polymerof primary hydroxyl alkyl usually has a higher hydrolysis rate than acomparable polymer of a secondary hydroxyl alkyl, which in turn usuallyhas a higher hydrolysis rate than a comparable polymer of a tertiaryhydroxyl alkyl. Thus, depending on the desired hydrolysis rate a polymerderived from a primary, secondary respectively tertiary hydroxyl alkylmay be preferred.

Preferably, the polymer is a homo or interpolymer of aN-(2-hydroxyalkyl) (meth)acrylamide modified with a hydrophobic unit,such as a lactate, an alkyl or an aryl.

More preferably, said polymer is selected from the group consisting ofhomopolymers and interpolymers of (hydrophobically modifiedN-(2-hydroxyethyl) methacrylamide), (hydrophobically modifiedN-(2-hydroxyethyl) acrylamide), (hydrophobically modifiedN-(2-hydroxypropyl) methacrylamide) and (hydrophobically modifiedN-(2-hydroxypropyl) acrylamide).

In an embodiment, the polymer is hydrophobically modified by amonolactate, a dilactate, a trilactate or a tetralactate, preferably amonolactate or a dilactate of the said hydroxyalkyl (meth)acrylamides.The polymer may be a copolymer or a blend of different hydrophobicallymodified hydroxyalkyl (meth)acrylamide polymers.

In an embodiment the blend or copolymer is a blend respectivelycopolymer of at least two polymers respectively chemically bound polymerunits according to the invention having a different number of lactatemoieties.

The presence of a lactate polymer other than the monolactate anddilactate (i.e. the presence of trilactate, tetralactate or higher) mayin particular be useful for providing a polymer(blend) with a relativelylow cloud point (CP), in particular a CP below 20° C., thus providing ablend or copolymer (aggregate) with improved stability under ambientconditions. For such purpose a tetralactate polymer according to theinvention is considered particularly suitable. The amount of higherlactates may be chosen within wide limits. Good results have beenachieved with a copolymer, in particular a pHEMAm-dilactaat, wherein atleast 5% of the monomers are other than mono- and dilactate. For goodwater solubility not more than 22% of the monomers are other than mono-and dilactate. Further, a polymer according to the invention with one ormore lactate side chains of at least three lactic acid units(trilactate), in particular of at least four lactic acid units(tetralactate) has been found suitable to provide micelles of thepolymer with improved stability, compared to the analogous polymercomprising only mono-, or dilactate units. It should be noted that thisin particular holds true for polymers further comprising a hydrophilicgroup (e.g. PEG) as will be discussed in detail below A polymeraccording to the invention preferably has a lower critical solutiontemperature before incubation below mammalian body (i.e. core)temperature, more preferably below ambient temperature (in particularbelow 20° C.). In addition the lower critical solution temperature afterincubation is preferably above mammalian body temperature (i.e. coretemperature). In a preferred embodiment the mammalian body temperatureis human body temperature, i.e. above about 37° C.

In addition, the invention relates to a blend of polymers comprising oneor more polymers according to the invention. Particularly suitableblends include a blend of hydroxyethyl (meth)acrylamide lactate and atleast one other hydroxyalkyl (meth)acrylamide lactate respectively ablend of hydroxypropyl (meth)acrylamide lactate and at least one otherhydroxyalkyl (meth)acrylamide lactate. Preferably, thehydroxyethyl/propyl and/or alkyl moieties are N-(2-hydroxyethyl),N-(2-hydroxypropyl), respectively N-(2-hydroxyalkyl).

The invention further provides a controlled release system comprising atemperature sensitive polymer according to any one of the precedingclaims and an active ingredient, such as a drug. Particularly suitabledrugs include hydrophobic drugs with a low water-solubility. Such drugsinclude paclitaxel and other cytostatics, amphoteracin, corticosteroids,and photosensitizers.

In a preferred embodiment, the controlled release system comprises thepolymer according to the invention in the form of a polymeric micelle.In such an embodiment, the polymer usually comprises a hydrophilic blockwhich preferably comprises a polyalkyleneglycol, more preferably apoly(ethyleneglycol). The number average molecular weight of thehydrophilic block (as determined by size exclusion chromatography) ispreferably in the range of about 500-10000 g/mol. The polymer capable offorming the micelle may be of the type AB, ABA or BAB (wherein A and Bare respectively the hydrophilic and hydrophobic block) In an embodimentthe controlled release system is in the form of a hydrogel. Inparticular in such an embodiment, the polymer according to the inventionis an ABA block copolymer or a BAB block copolymer, wherein block A isthe temperature sensitive hydrophobically modified poly(hydroxyalkyl(meth)acrylamide) as defined herein and B is a hydrophilic polymer,preferably a polyalkyleneglycol, more preferably a poly(ethyleneglycol).The number average molecular weight of the hydrophilic block (asdetermined by size exclusion chromatography) is preferably in the rangeof about 500-10000 g/mol.

The invention further relates to a targeting drug composition,comprising a drug and particles of a controlled release system accordingto the invention, which particles preferably have a weight averagediameter of less than 200 nm, more preferably in the range of 10 to 100nm (as determined by dynamic light scattering)

In an embodiment, the targeting drug composition comprises a homingdevice.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a light scattering curve, wherein both the temperature atthe point of inflection and the onset temperature are marked.

FIG. 2 gives the structure of poly(HPMAm-monolactate) (n=0),poly(HPMAm-dilactate) (m=0) andpoly(HPMAm-monolactate-co-HPMAm-dilactate) (m, n≠0).

FIG. 3 shows a light scattering intensity temperature curve forpoly(HPMAm-monolactate-co-HPMAm-dilactate) in isotonic 120 mM ammoniumacetate buffer (pH=5.0) at 5 mg/ml. The molar ratio of HPMAm-monolactateto HPMAm-dilactate is 51:49 (mol/mol).

FIG. 4 shows the Cloud Point (CP) ofpoly(HPMAm-monolactate-co-HPMAm-dilactate) as a function of the mole-%HPMAm-monolactate in the copolymer. • is 1 mg/mL solution in water; ▪ is1 mg/mL solution in isotonic 120 mM ammonium acetate buffer (pH=5.0).

FIG. 5 shows the CP of poly(HPMAm-monolactate-co-HPMAm-dilactate 51/49)in isotonic 120 mM ammonium acetate buffer (pH=5.0) as a function of thepolymer concentration.

FIG. 6 shows stability data on poly(HPMAm-dilactate)-b-PEG (M_(n)-'srespectively 13600/5000) micelles at 37° C. and at pH=5.0 (top) andpH=9.0 (bottom).

FIG. 7 shows the CP of a copolymer of the invention (pHEMAm-lactate) asa function of the tetralactate content in the polymer

FIG. 8 shows a CryoTEM picture of a micellar solution of a polymeraccording to the invention. FIG. 9 shows a plot for determining the cmcof a polymer according to the invention. FIG. 10 shows the effect of theconcentration of a polymer according to the invention on the particlesize of the micelles. FIG. 11 shows the particle size stability ofPEG-b-p(HEMAm-dilactate) versus time FIG. 12 shows the particle sizestability of another polymer according to the invention

DETAILED DESCRIPTION OF THE INVENTION

The drug delivery systems based on LCST-polymers can be preparedconveniently by introduction of the drug (such as a protein, a lowmolecular weight drug or another biologically active agent) into thepolymer matrix. This is obtained by mixing the drug with the polymer,which is in dissolved state, for example because it is below its LCST.Subsequently, the mixture is brought in a state in which the polymerprecipitates, for example by bringing it above its LCST, by whichprocess the protein drug is captured within the precipitating polymermatrix, thus yielding a drug delivery system.

For the use in drug delivery systems, it is essential that theLCST-polymer to be applied is above its critical solubility temperature.Effective application as controlled release system can only be obtainedwhen the in vivo temperature is above the critical solution temperature.Although it is known in the art—see e.g. the above discussedpublications—that LCST-polymers can be modified by changing theircomposition, it will be clear that a choice with respect to the LCST hasto be made prior to the administration. Once a certain polymer ischosen, its LCST is fixed. Variations of the application temperatures,as can occur easily for example as a result of differences or variationsin body temperature, can lead consequently to different and non-gradualrelease profiles.

Said in other words, for biomedical and pharmaceutical applications ofthermosensitive polymers, it is important to have possibilities tocontrol the CP around body temperature. Furthermore, polymers of whichthe CP's increase from below to above body temperature in time are veryattractive materials, because e.g. the controlled release of drugswithout thermal treatment is feasible using such polymers.

The present invention provides a polymer that is suitable for use in acontrolled release system. Consequently, this polymer can be applied asa controlled release system having all the aforementioned advantages.

The present inventors have found that when certain water solublepolymers are chemically modified, their critical solution temperaturewill vary in situ, viz. upon in vivo or in vitro application in anaqueous environment. These changes are time dependent. In thisdescription and the appending claims, application in an aqueousenvironment, under conditions enabling the reactions that result in thechange of critical temperature, for example as a result of hydrolysis,is referred to as incubation. It is also possible that the incubation iseffected by enzymes present in the aqueous environment.

The polymer of the present invention comprises monomers which havemodifiable functionality. The functionality of the monomers can forexample be modified by the presence of hydrolysable groups. Themodification is effected by the incubation, leading to a change of thewater solubility characteristics of the polymer.

When reference is made to a polymer in this description, alsohomopolymers, copolymers, terpolymers, graft polymers, (highly) branchedpolymers and other interpolymers are to be understood. In fact,copolymers and terpolymers have the additional advantage that theyprovide an extra parameter affecting the final result, since differentmonomers, having different solubility characteristics, can beincorporated in one polymer, as to adjust the solubility characteristics(such as the solubility itself or the temperature dependency of thesolubility) of the resulting copolymer. Copolymers and terpolymers thusform a preferred embodiment of the present invention.

The polymer according to the present invention is suitably obtained bychoosing the properties of the monomers such that upon incubation thefunctionality of the monomers changes and as a result the solubilityand/or the temperature dependency of the solubility of the entirepolymer, changes. in a particular embodiment, the monomers are chosen sothat their hydrophilicity changes upon incubation. As a result, thehydrophilicity of the entire polymer will change upon incubation. Thiswill lead to a polymer with a different solubility and/or temperaturedependency of the solubility.

As indicated above, poly(NIPAAm-co-HPMAm-lactate)-b-PEGm, as describedin WO 01/09198 may show controlled instability at body temperature. Uponfurther investigation, the present inventors have realised that thebiodegradability of PNIPAAm should be improved. Moreover, thebiocompatibility and possible toxic-side effects of PNIPAAm are notwell-known at present. In their investigations, the present inventorshave found that a favorable system can be based on HPMAm and/or otherhydroxyalkyl (meth)acrylamide based polymers that are hydrophobicallymodified by a hydrolysable group.

The hydrolysable group may for instance be bound by a bond selected fromesters, orthoesters, amides, carbonates, carbamates, anhydrides, ketals,and acetals, preferably by an ester bond.

The present invention therefore in particular relates to a novel classof such thermosensitive and biodegradable polymers which may bedescribed as poly(hydroxyalkyl (meth)acrylamide lactate), wherein thenumber of lactates per hydroxyalkyl (meth)acrylamide is generally 1, 2,3, 4, 5, 6, 7, 8, 9 or 10. Such a polymer may be represented by thefollowing formula of the monomeric units constituting the polymer:

wherein R is the alkyl (which may be linear or branched) and n thenumber of lactate moieties. The ester moiety may be coupled to the R atany position of the alkyl chain, Thus the position of the ester relativeto the amide may be α, β, γ, δ, ε (etc), or ω position.

Particular suitable examples of polymers according to the invention are(homo)polymers of a (N-2-hydroxypropyl) methacrylamide lactate,(N-2-hydroxyethyl) methacrylamide lactate, (N-hydroxymethyl)methacrylamide lactate, (N-2-hydroxybutyl) methacrylamide lactate,(N-2-hydroxypentyl) methacrylamide lactate or (N-2-hydroxyhexyl)methacrylamide lactate.

Especially favoured are poly(N-(2-hydroxypropyl) methacrylamide mono/dilactate) (poly(HPMAm-mono/di lactate)), poly(N-(2-hydroxyethyl)methacrylamide mono/di lactate) (poly(HEMAm-mono/di lactate)),poly(N-(hydroxymethyl) methacrylamide mono/di lactate)(poly(HMMAm-mono/di lactate)), poly(N-(2-hydroxybutyl) methacrylamidemono/di lactate) (poly(HBMAm-mono/di lactate)), poly(N-(2-hydroxypentyl)methacrylamide mono/di lactate) (poly(HPeMAm-mono/di lactate))respectively poly(N-(2-hydroxyhexyl) methacrylamide mono/di lactate)(poly(HHMAm-mono/di lactate)).

In the present description and the appending claims, the term“interpolymer” refers to a polymer comprising at least two types ofmonomers, and hence encompasses copolymers, terpolymers, etc.

Preferably, the invention relates to homopolymers of HPMAm-dilactate,HEMAm-dilactate and other hydrophilic monomers such asHEMAm-monolactate, HPMAm-monolactate, HEMAm-(lactate)_(n),HPMAm-(lactate)_(n), wherein n is an integer from 3 to 10, in particularfrom 3 to 5; HPMAm; or hydroxy(C₁₋₆ alkyl)methacrylate. Also terpolymersof poly(hydroxyalkyl (meth)acrylamide-mono/dilactate), such aspoly(HPMAm-mono/dilactate) or poly(HEMAm-mono/dilactate), and a furtherhydrophilic monomer are suitable to be used.

The cloud points (CP) of a poly(HPMAm-monolactate) andpoly(HPMAm-dilactate) in water were 65° C. and 13° C., respectively. Thelower CP for poly(HPMAm-dilactate) is likely due the greaterhydrophobicity of the dilactate side group over the monolactate sidegroup. The CP of poly(HPMAm-monolactate-co-HPMAm-dilactate) increasedlinearly with the mole percentage of HPMA-monolactate, whichdemonstrates that the CP is tuneable by the copolymer composition.Likewise, the CP of poly(HEMAm-dilacate-co-HEMAm-tetralactate) decreasedlinearly with the mole percentage of the more hydrophobicHEMAm-tetralactate.

Hence, in an aspect, the present invention relates to a temperaturesensitive polymer having a lower critical solution temperature thatchanges during incubation in an aqueous solution or medium, whichpolymer is a homo- or interpolymer of a (N-(hydroxyalkyl) methacrylamidelactate). In a preferred embodiment said N-(hydroxyalkyl) methacrylamidelactate is the mono- or dilactate, more preferably the dilactate. Thealkyl is preferably propyl or ethyl.

The term “mono/dilactate” means that part of the monomers used in thepolymers of the invention are in the monolactate form, and part or allof the monomers used in the polymers of the invention are in thedilactate form.

Due to the hydrolysable lactic acid side groups the CP will increase intime with lactic acid, an endogenous compound, and the water-solublepoly(hydroxyalkyl (meth)acrylamide) (such as pHPMAm, pHEMAm) asdegradation products. In particular, pHPMAm is a well-known non-toxicmacromolecular carrier which is, among others, used for the developmentof polymeric prodrugs of cytostatic agents. A good biocompatibility of apolymer according to the invention is expected, in particular forpoly(HPMAm-lactate), especially because pHPMAm systems have recentlyentered into clinical trials.

The polymer can be synthesized by starting from a mixture of themonomers and carrying out the polymerization reaction. It is alsopossible to first produce the polymer and subsequently functionalize itby coupling suitable groups. Compositions according to the presentinvention comprise block copolymers or terpolymers, random copolymers orterpolymers, random copolymers and polymeric networks, all of whichpolymers can be grafted, and mixtures (blends) thereof.

The solubility characteristics of the compositions according to thepresent invention will change upon incubation, for example whencontacted with aqueous media, such as will be the case in in vivoapplication.

For application in mammals, the polymers according to the presentinvention have a critical temperature for the composition as synthesizedwhich is below body temperature and preferably below ambienttemperature, viz. between about 0 to 36° C., preferably between 0 and20° C., and most preferably between 5 and 10° C. However, morepreferably the value of LCST crosses the normal human body temperature(which is typically 37° C.) upon incubation so that the LCST beforeincubation is below 37° C., preferably below 20° C., and LCST afterincubation is above 37° C., preferably above 38° C.

A preferred embodiment of the present invention is the use of thetemperature sensitive polymer in or as a controlled release system whichfurther comprises an active ingredient. Such systems are for examplesuitable for the controlled administration of drugs, such as proteindrugs.

The controlled release system of the present invention can be used forthe release of biologically active compounds, such as pharmaceuticcompounds, e.g. pharmaceutically active peptides and proteins, geneticmaterial e.g. nucleotides, RNA and DNA, plasmid DNA, anti-senseoligonucleotides, si-RNA, nutrients, low molecular drugs, imagingagents, etc. As mentioned above, hydrogels are especially suitable forthe release of proteins and similar compounds, whereas micellar systemsare suitable as carriers for low molecular weight drugs.

When the system is used for the delivery of genetic material, e.g. thedelivery of plasmid DNA, anti-sense oligonucleotides or si-RNA, the LCSTpolymer of the invention preferably comprises cationic groups, such asDMAEMA (=dimethyl amino ethyl methacrylate).

It is also possible to make the controlled release systems which can beobtained by the present invention in the form of polymeric micelles.Polymeric micelles can be formed by the synthesis of amphiphilicblockcopolymers, e.g. AB block copolymers of a polyalkylene glycol, suchas PEG, and a hydrophobic or thermosensitive block. In aqueoussolutions, these polymers form micelles with a size of around 20-100 nmsimilar to those of the method of G. S. Kwon, et al. Langmuir, 9 (1993),945-949). The hydrophobic core of these micelles can be loaded withdrugs, e.g. an anti-cancer agent, such as adriamycin or paclitaxel).After in vivo administration of these systems the adriamycin loadedmicelles selectively accumulate in certain tumors, simultaneouslyreleasing the drug, which results in killing of tumor cells (cfr. M.Yokoyama, et al. Journal of Controlled Release, 50 (1998) 79-92).

Polymers with an LCST have also been applied to design polymericmicelles. Below the LCST, the thermosensitive polymer acts ashydrophilic part of the system (e.g. in AB blockcopolymers of NIPAA andstyrene; cfr. S. Cammas, et al. Journal of Controlled Release, 48 (1997)157-164).

Also, systems have been described in which PNIPAA forms the hydrophobicpart of the polymeric micelle (in block copolymers of poly(ethyleneglycol) and poly(N-isopropylacrylamide); M. D. C. Topp, et al.Macromolecules, 30 (1997) 8518-8520). After administration of these drugloaded PNIPAA systems and arrival at the target site, drug release canthen be triggered by local hypothermia. Hypothermia is, however, noteasily done or technically feasible for all tissues and organs, whichlimits the applicability of these systems.

These disadvantages can be overcome by using polymers composed of ahydrophilic block covalently linked to a block composed ofthermosensitive polymer with hydrolyzable side groups. Such ahydrophilic block preferably comprises a polyalkylene glycol, inparticular a poly(ethyleneglycol) (PEG). When the LCST of thethermosensitive block is initially below body temperature, polymericmicelles are formed at 37° C. Due to hydrolysis of the side groupspresent in the thermosensitive block of the system, the LCST willincrease, resulting in destabilization of the micelle when the LCSTpasses 37° C. When a drug is incorporated in the hydrophobic core, itsrelease will be affected by this process. These systems can be favorablyapplied in e.g. cancer treatment, treatment of rheumatism, arthritis,infections and/or other inflammations.

As mentioned above, the polymers of the present invention comprise allpossible polymer architectures, such as (multi-)block copolymers (suchas AB, ABA, ABAB, etc.) or graft copolymers, random copolymers orterpolymers, or polymeric networks; all of which may be grafted.

AB blockcopolymers with a thermosensitive block A (i.e. the block of thehydrophobically modified hydroxyalkyl (meth)acrylamide) polymer of theinvention) and a water-soluble B block (e.g. PEG or pHPMAm) that formmicelles when the LCST is passed, can be obtained by any known techniquein the art for making AB blockcopolymers. Conveniently, these polymersare prepared using a so called macroinitiator.

A macroinitiator is a macromolecular initiator that is formed e.g. bycoupling a low molecular weight initiator, such as4,4′-azobis(4-cyanopentanoic acid), (HO—CO—CH₂—CH₂—C(CH₃)(CN)—N═)₂(ABCPA), via its carboxyl groups at to the terminal OH group of acompound such as methoxylated PEG (i.e. CH₃—O-PEG-OH). In this way acompound of the formula (CH₃—O-PEG)₂-ABCPA is formed. Typically, PEGwith a Mw of about 500-10000 g/mol, in particular of about 1500-10000g/mol, is used for this purpose. Preferably PEG with a Mw of about 5000g/mol (PEG 5000) is used to form a (PEG 5000)₂-ABCPA macroinitiator.When this initiator decomposes by heat, a PEG chain with one radical isformed. This radical subsequently initiates the polymerization ofmonomers (such as HPMAm-mono- and dilactate, as described hereinbelow),by which an AB block copolymer is formed. In aqueous solution suchpolymers form a micellar structure when the temperature rises above itsLCST. These micelles destabilize when the hydrolysis results in an Ablock with an increased LCST (above the temperature at which themicelles are applied, preferably at body temperature). Alternatively,the block copolymers can be prepared by controlled radicalpolymerization techniques such as atom transfer radical polymerization(ATRP) or reversible addition-fragmentation chain transfer (RAFT)polymerization using macroinitiators, macro-RAFT-agents, or sequentialmonomer addition.

ABA block copolymers may be synthesized via any of the above mentionedtechniques, e.g. the macroinitiator route by using instead of amonofunctional (i.e. α-methoxy) PEG or equivalent thereof, anα-ω-hydroxyl derived macroinitiator, uiz. a polyester macroinitiatorwhich has the ABCPA-groups alternating with PEG groups. When thisinitiator decomposes by heat, PEG chains with two radicals are formed.These radicals subsequently initiate the polymerization of monomers(such as HPMAm-mono- and dilactate), by which an ABA block copolymer isformed. The ABA block copolymers formed by this route will be soluble inwater below the LCST. When the temperature is risen above the LCST ofblock A, a phase separated system will be formed, wherein as a result ofthe choice of block copolymer architecture, a hydrogel will be obtained.This hydrogel will dissolve gradually when the LCST of block A increasesto above 37° C., due to the hydrolysis of the groups present on themonomers of this block. These systems are especially suitable forimmobilizing cells, which can be employed in biotechnology and tissueengineering. Like the other systems mentioned hereinabove, thesehydrogel systems can also be used as matrix for controlled release ofactive ingredients, in particular pharmaceutical proteins.

It is noted, however, that also the ABA block copolymers—like the ABblock copolymers—may also be prepared by other, conventional synthesisroutes, as indicated above (e.g. by RAFT polymerization).

In Examples 3 and 4 herein-below, the synthesis of AB and ABA blockcopolymers are illustrated.

The controlled release system of the present invention may be in theform of a hydrogel. The hydrogel may comprise an ABA block copolymerwherein block A is a temperature sensitive polymer according to theinvention and B is a hydrophilic polymer and preferably it is PEG. SuchABA block copolymers and hydrogels have the advantages described above.

When the polymers of the present invention are used for targeting drugpurposes, the release system is made of particles, which particles havean average diameter of less than 1 μm, preferably less than 100 nm. Tobe of practical value, these particles will usually have to be largerthan several nm, e.g. greater than 10 nm as determined by lightscattering.

The ratio of different monomers, and especially the mono/dilactate ratiowhich constitute the interpolymer of the invention, will influence theLCST and its development upon incubation. Generally for practicalapplication, e.g. application in mammals, it is desirable to choose theratios such that the LCST before incubation is below body temperatureand after incubation above body temperature. The optimal ratio of eachof the monomers will consequently depend strongly on the materials usedand the envisaged application. The optimal values can be determinedexperimentally, as will be illustrated in the Examples hereinafter.

An important aspect of the present invention is the use of hydrolysablechemical groups in a temperature sensitive polymer in order to changesaid polymer's solution characteristics, specifically its criticalsolution temperature, more specifically its lower critical solutiontemperature (LCST).

It will be understood that apart from changing the solubility ofpolymers having a lower critical solution temperature, this can also beapplied to polymers having a higher critical solution temperature, viz.polymers which dissolve at temperatures higher than their criticaltemperature, and precipitate at temperatures lower than this criticaltemperature.

The effect of the incubation can be an increase as well as a decrease ofthe critical temperature upon incubation.

The controlled release systems of the present invention can be preparedby the synthesis of a water soluble polymer. This is e.g. done by a)functionalizing a monomer with hydrolysable groups, b) optionally mixingof said monomer with at least one monomer of a different type in asuitable ratio using a suitable solvent in the presence of an initiatorand/or a catalyst to form said polymer c) removing said solvent anddissolving the polymer, and d) optionally purify said polymer, such asby precipitation; in which process the functionalizing of the monomersof step a) is optionally carried out after step b) on the monomers asthey are present in the polymer; and subsequently mixing said watersoluble polymer with a releasable compound.

Suitable initiators and catalysts are known in the art. An example of asuitable initiator for step b) is α,α′-azoisobutyronitrile (AIBN). Anexample of a suitable catalyst for step a), (e.g. the grafting of HPMAm,HEMam or the like with lactide), is stannous octoate (SnOct₂).

The polymer of the present invention comprises one or morehydrophobically modified hydroxyalkyl methacrylamide monomers. Inparticular the monomers may be selected from monolactate, dilactate orhigher lactate esters of the said monomers. With respect to the higherlactate, this is usually chosen in the range of 3 (trilactate) to 10(decalactate). The hydroxyalkyl methacrylamide (such as HPMAm, HEMAmetc.) can be synthesized based upon the technology as described by D.Oupicky et al. (DNA complexes with block and graft polymers ofN-2-hydroxypropyl)methacrylamide and 2-(trimethylammonio)ethylmethacrylate. J. Biomater. Sci. Polymer Ed., Vol. 10, No. 5, pp. 573-590(1999).

The hydroxyalkyl methacrylamide (such as HPMAm, HEMAm etc.) cansubsequently be esterified to mono, dilactate and higher lactate withlactide based upon the methodology as described by Neradovic. D, et al.(Degradation mechanism and kinetics of thermosensitive polyacrylamidescontaining lactic acid side chains. Macromolecules 36, 7491-7498,(2003)).

In principle, other monomers can be present as well. All monomers thatcopolymerize with the hydrophobically modified hydroxyalkylmethacrylamide (such as HPMAm-lactate, HEMAm-lactate etc) are suitable.Examples of these are acrylates, methacrylates, acrylamides,methacrylamides, N-vinyl-pyrrolidone, vinyllactates, vinylethers, etc.The amount of these comonomers that can be present will vary upon thespecific monomers in question and is from 0-70 mole %, preferably from1-50 mole %. The critical issue is the LCST behaviour, which should bemaintained.

A specific polymerization reaction giving the polymers of the inventionis described hereinbelow in Example 1.

Apart from application as a controlled release agent, the polymers ofthe present invention can be applied as release systems for a variety ofcompounds in different applications, such as enzymes, colorants or otheradditives in laundry applications, adhesives in glues, insecticides ornutrients in agricultural applications, etc. Also possible is the usefor the entrapment of living cells for e.g. tissue engineering (see, inthis respect, Lee K. Y. Mooney, D. J. Hydrogels for tissue engineering,Chemical Reviews 2001: 101, 1869-1879) Further possible applications arethe topical administration polymers of the present invention loaded withactive ingredients, e.g. for the treatment of burn wounds and ulcers.The polymers of the invention can also be used for the delivery ofgenetic material (DNA delivery).

The present invention will now be illustrated in the following Examples,which illustrate the invention and are not limiting the invention.

EXAMPLE 1 Synthesis of poly(HPMAm-monolactate), poly(HPMAm-dilactate)and Their Copolymers

HPMAm-monolactate and HPMAm-dilactate (synthesized as described byNeradovic et al, Thermoresponsive polymeric micelles with controlledinstability based on hydrolytically sensitive N-isopropylacrylamidecopolymers. Macromolecules 34, 7589-7591, 2001) were dissolved at aconcentration of 0.1 g/mL in 1,4-dioxane. TheHPMAm-monolactate/HPMAm-dilactate ratios were 100/0, 75/25, 50/50,25/75, 0/100 (mol/mol). α,α′-Azoisobutyronitrile (AIBN) (total amount ofmonomers/AIBN is around 40/1 (mol/mol)) was added as radical initiatorand the polymerization was conducted at 70° C. for 24 h in a nitrogenatmosphere. The polymers were collected by centrifugation afterprecipitation in diethyl ether. The polymers were further purified bydissolving them in cold water, followed by filtration through a 0.22 μmfilter. After freeze-drying, the products were characterized by ¹H NMR(solvent: CDCl₃) and gel permeation chromatography (GPC). GPC was doneusing Plgel 3 μm MIXED-D+Plgel 3 μm MIXED-E columns (PolymerLaboratories) and poly(ethylene glycol) standards. The eluent was DMFcontaining 10 mM LiCl, the elution rate was 0.7 mL/min. and thetemperature was 40° C. The copolymer composition of the polymers wasdetermined by ¹H NMR from the ratio of the integral of the peak at 5.0ppm (I_(5.0), methine protons 1 and 2, FIG. 2) to the integral of thepeak at 4.3 ppm (14.3, methine protons 3, FIG. 2) by the followingformula: I_(5.0)/I_(4.3)=1+x, where x represents the molar fraction ofHPMAm-dilactate in the copolymer.

The CP of the polymers was determined with static light scattering (SLS)using a Horiba Fluorolog® fluorometer (650 nm, at a 90° angle). Thepolymers were dissolved in water or in isotonic 120 mM ammonium acetatebuffer (pH=5.0) at 0° C. The polymer concentration was varied between0.1 mg/mL and 5 mg/mL. The scattering intensity was measured every 0.2°C. during heating and cooling (the heating/cooling rate wasapproximately 1° C./min). Onsets on the X-axis, obtained byextrapolation of the intensity-temperature curves during heating tointensity zero were considered as the CP. The CP determinations weredone at least two times and the deviations were smaller than 0.5° C.

The results of the Example are discussed herein-below.Poly(HPMAm-monolactate), poly(HPMAm-dilactate) as well as theircopolymers (FIG. 2) were synthesized by radical polymerization. Fivepolymers with different monomer compositions were obtained in a yieldbetween 50 and 70% (see Table 1).

TABLE 1 Characteristics of the polymers prepared in Example 1 Feed Ratioin ratio polymer^(a)) CP CP (mol/mol) (mol/mol) M_(n) ^(b)) M_(w) ^(b))M_(w)/M_(n) (° C.)^(c)) (° C.)^(d)) poly(HPMAm- 100/0  — 11400 244002.14 65.0 63.0 monolactate) poly(HPMAm- 75/25 75/25 7500 17600 2.35 50.547.5 monolactate- 50/50 51/49 8100 16900 2.08 36.5 34.0 co-HPMAm- 25/7526/74 6800 14000 2.06 25.0 23.0 dilactate) poly(HPMAm-  0/100 — 630010700 1.70 13.0 10.5 dilactate) ^(a))Determined by ¹H NMR. ^(b))M_(n) =number average molar weight; M_(w) = weight average molar weightdetermined by GPC ^(c))Determined by SLS for 1 mg/mL solution in water.^(d))Determined by SLS for 1 mg/mL solution in isotonic 120 mM ammoniumacetate buffer (pH = 5.0).

For the copolymers, the composition was close to the feed ratio of themonomers. Static light scattering measurements of these polymers inwater and in isotonic 120 mM ammonium acetate buffer (pH=5.0, tominimize hydrolysis of lactate ester side group) were performed.Interestingly, all polymers of Table 1 showed LCST behaviour. FIG. 3shows a typical light scattering intensity-temperature curve forpoly(HPMAm-monolactate-co-HPMAm-dilactate) in isotonic 120 mM ammoniumacetate buffer (pH=5.0). Poly(HPMAm-monolactate) has a rather high CP(65° C. in water, Table 1) whereas poly(HPMAm-dilactate) has arelatively low CP (13° C. in water, Table 1). This can be explained bythe greater hydrophobicity of the dilactate side group over themonolactate side group. Importantly, the CP of the copolymers linearlyincreased with mol % of HPMA-monolactate monomer (FIG. 4), meaning thatthe CP of the copolymers can be tailored by the copolymer composition.

Although molecular weight of the polymers decreased as the ratio ofHPMAm- dilactate increased (Table 1), the decrease of molecular weightis not the reason for the decrease of the CP. Poly(HPMAm-monolactate)with lower molecular weight was prepared and it was observed that the CPslightly increased with the decrease of molecular weight.

The CP's in isotonic 120 mM ammonium acetate buffer (pH=5.0) wereapproximately 2.5° C. lower than those in water (Table 1). This can beattributed to a salting-out effect of ions present in the buffersolution. FIG. 3 shows that thermohysteresis of around 5° C. is observedbetween the heating and cooling curve. It has been reported that PNIPAAmdoes not show LCST hysteresis. In contrast,poly(N-isopropylmethacrylamide) shows hysteresis, which is ascribed tothe α-methyl group in the polymer backbone resulting in a decreasedchain flexibility.

Since the polymers of Table 1 also contain α-methyl groups in thepolymer backbone, the hysteresis is likely due to the same phenomenon.

FIG. 5 shows the effect of the concentration of polymer on the CP. TheCP decreased approximately 3° C. as the concentration increased 10-fold.The CP of PNIPAAm is hardly affected by its concentration, while otherthermosensitive polymers also show an increase of CP with a decrease inconcentration.

The thermosensitive and biodegradable polymers of the invention haveattractive features especially as materials for drug delivery andbiomedical applications. First, the CP of the polymer can be tailoredfrom 10° C. to 65° C. by the copolymer composition. Second, the lacticacid side groups are removed by hydrolysis in time. This means that thepolymer becomes more hydrophilic in time, which is associated with anincrease in CP. Therefore, polymers can be designed which are initiallyin their precipitated form but which become soluble in time. Further, itis expected that the polymers possess a good biocompatibility.

EXAMPLE 2 Paclitaxel Loading into PEG-b-p(HPMAm-dilactate)

In this example the loading of Paclitaxel (PTX) into the micelles ofPEG5000-b-p(HPMAm-dilactate)13600 block copolymers was studied.Preparation of the block copolymers is described in example 3 below.

First, the polymer was dissolved at a concentration of 10 mg in 1 mlisotonic 120 mM ammonium acetate buffer with a pH of 5.0. Thetemperature was maintained at 0° C. by ice-cooling.

1.8 ml of this polymer solution or of the buffer as a reference wascooled with ice. Next a 0.2 ml PTX solution in ethanol was addedmeanwhile stirring and ice cooling the solution. To sample A and sampleB 10 mg/ml PTX solution was added and to sample C 20 mg/ml. The volumeratio of PTX solution and polymer solution is 1:9. Thus 10% ethanol(v/v) is present in the mixture.

Immediately after mixing the drug and polymer solutions, the mixture wasput into a water bath of 50° C. for 1 minute to form micelles. Next thesolution was left at room temperature for 1 minute and subsequentlyfiltrated with a 0.45 μm filter to remove precipitated PTX.

The DLS of the filtrate was measured at 25° C. and the amount of PTX byHPLC. The results are in Table 2 below.

TABLE 2 Sample B) C) A) PTX PTX PTX + buffer 1 mg/mL 2 mg/mL PTX 10001000 2000 added (μg/mL) Polymer 9 9 9 (mg/mL) % Ethanol 10 10 10 informulation Outlook lots of opalescent opalescent after formingprecipitates micelles PTX 1.4 1003 1847 loaded (μg/mL) Loading 100.3%92.4% efficiency (%) Z_(ave) (PD) — 59 nm 66 nm at 25° C. (0.059)(0.088)From Table 2 it is clear that the amount of loaded PTX increasesdramatically and almost linearly with the amount of polymer used.Furthermore, it is indicated that the average particle size Z is wellbelow 100 nm; for sample B 59 nm and for sample C 66 nm, respectively.

EXAMPLE 3

Synthesis of AB blockcopolymers of p(HPMAm-dilactate) (A-block) and PEG(B-block) (p(HPMAm-dilactate)-b-PEG block copolymers (pHPMAmDL-b-PEG)).p(HPMAm-dilactate)-b-PEG block copolymers (pHPMAmDL-b-PEG) weresynthesized by radical polymerisation using HPMAm-dilactate as monomerand PEG₂-ABCPA as macroinitiator essentially as described previously forthe synthesis of block-copolymers of PEG 5000 and NIPAAm orNIPAAm-HPMAm(-lactate) (Neradovic D, Van Nostrum CF, and Hennink WE.Thermoresponsive polymeric micelles with controlled instability based onhydrolytically sensitive N-isopropylacrylamide copolymers.Macromolecules 34, 7589-7591, 2001) and schematically shown in scheme 1.

The macroinitiator (PEG 5000)₂-ABCPA was synthesized as follows. A 50 mLround bottom flask was loaded with 2 g (0.4 mmol) polyethylene glycol5000 monomethylether (PEG 5000), 0.056 g (0.2 mmol)4,4-azobis(4-cyanopentanoic acid) (ABCPA), 0.0189 g (0.06 mmol)4-(dimethylamino)-pyridinium-4-toluene-sulfonate (DPTS) and 0.125 g (0.6mmol) N,N′-dicyclohexylcarbodiimide (DCC). The flask was evacuated andfilled with nitrogen. Next, 3 mL of 1:1 mixture of dichloromethane(stabilized with amylene) and dry DMF was added using a syringe. Themixture was stirred at room temperature for 24 hours. Next, the reactionmixture was filtered, the solid was washed with dichloromethane and thecombined organic solutions were evaporated.

Thereafter, the product was dissolved in toluene, remaining insolublesubstances were removed by filtration, and the solvent was evaporated.The obtained dry product was extracted with diethyl ether to removetraces of dicyclohexyl urea (DCU). The product obtained was dissolved inwater and the solution was filtered to remove remaining solid. Theproduct was collected after freeze-drying (yield 80%). Thismacroinitiator is used for the synthesis of p(HPMAm-dilactate)-b-PEGblock copolymers (pHPMAmDL-b-PEG). In detail: HPMAm-dilactate andPEG₂-ABCPA were dissolved at a total concentration of 0.3 g/mL inacetonitrile. To obtain block copolymers with different pHPMAmDL blocklengths, the ratio of monomer to macroinitiator was varied between 35/1to 140/1 (mol/mol).

The polymerization was conducted at 70° C. for 24 hours in a nitrogenatmosphere. The polymers were collected by centrifugation afterprecipitation in diethyl ether. The polymers were further purified bydissolving these in cold water, followed by filtration through a 0.22 μmfilter and freeze-drying. The products were characterized by ¹H NMR(solvent: CDCl₃) with a Gemini 300 MHz spectrometer (Varian AssociatesInc. NMR Instruments, Palo Alto, Calif.) and gel permeationchromatography (GPC). GPC was carried out using Plgel 3 μm MIXED-D+Plgel3 μm MIXED-E columns (Polymer Laboratories) and poly(ethylene glycol)standards. The eluent was DMF containing 10 mM LiCl; the elution ratewas 0.7 mL/min; and the temperature was 40° C.

¹H NMR (solvent: CDCl₃) (all protons are from pHPMAmDL block except formethylene protons from PEG.): δ=6.5 b, CO—NH—CH₂), 5.0 (b,NH—CH₂—CH(CH₃)—O and CO—CH(CH₃)-O), 4.4 (b, CO—CH(CH₃)—OH), 3.6 (b, PEGmethylene protons, O—CH₂—CH₂), 3.4 (b, NH—CH₂—CH(CH₃)), 2.0-0.6 (therest of the protons from pHPMAmDL block).

The number average molecular weight (M_(n)) of pHPMAmDL block wasdetermined by ¹H-NMR as follows: a) the value of the integral of the PEGprotons divided by 454 (average number of protons per one PEG 5000chain) gave the integral value for one PEG proton and b) the number ofHPMAmDL units in the polymers was determined from the ratio of theintegral of the methine proton (CO—CH(CH₃)—OH) of HPMAmDL to theintegral of one PEG proton. The number average molecular weight of thepHPMAmDL block was calculated from the resulting number of units.

Determination of the Critical Micelle Temperature (CMT) of the DifferentBlock Copolymers.

The CMT of block polymer solution was determined with static lightscattering using a Horiba Fluorolog fluorometer (650 nm, at a 90°angle). The polymers were dissolved at a concentration of 10 mg/mL inisotonic 120 mM ammonium acetate buffer (pH=5.0) at 0° C. The scatteringintensity was measured every 0.2° C. during heating and cooling (theheating/cooling rate was approximately 1° C./min). Onsets on the X-axis,obtained by extrapolation of the intensity-temperature curves duringheating to intensity zero were considered as the CMT. The CMTdeterminations were done at least two times and the deviations weresmaller than 0.5°C.

Formation of micelles.

Micelles of block copolymers were formed by quickly heating an aqueouspolymer solution from below to above CMT. The polymers were dissolved ata concentration of between 0.1 to 20 mg/mL in isotonic 120 mM ammoniumacetate buffer (pH=5.0) at 0° C. in glass vials. Next, the polymersolution was quickly brought from 0° C. to 50° C. and was left at 50° C.for 1 minute. Before dynamic light scattering measurements, the micellesolution was incubated at 37°° C.

Size measurements of the micelles.

Dynamic light scattering (DLS) measurements were done to determine thesize of the micelles, using Malvern 4700 system (United Kingdom)consisting of an Autosizer 4700 Spectrometer, a pump/filter unit, aModel 2013 air-cooler Argon ion laser (75 mW, 488 nm, equipped with amodel 2500 remote interface controller, Uniphase) and a computer withDLS software (PCS, version 3.15, Malvern). The measurement temperaturewas 37° C. and the measurement angle was 90°. The change in solventviscosity with temperature was corrected by the software.

Determination of the critical micelle concentration (cmc).

The critical micelle concentration (cmc) of the different blockcopolymers was determined using pyrene as a fluorescence probe. Micellesof block copolymers were formed as described above in isotonic 120 mMammonium acetate buffer (pH=5.0) at a concentration of 2 mg/mL. Themicelle solutions with different polymer concentrations ranging from to0.00001 mg/mL to 1.0 mg/ml were obtained by diluting the polymersolution with the same buffer at room temperature. Pyrene was dissolvedin acetone at 1.8×10⁻⁴ M and 15 μL of this solution was added to 4.5 mLof micelle solution, which gave 6.0×10⁻⁷ M of pyrene in the mixture. Themicelle solutions with pyrene were equilibrated at room temperature inthe dark for 20 hours to allow the evaporation of acetone. Fluorescenceexcitation spectra of pyrene were obtained using a Horiba Fluorologfluorometer (at a 90° angle). The excitation spectra were recorded at37° C. from 300 to 600 nm with the emission wavelength at 390 nm. Theexcitation and emission band slits were 4 nm and 2 nm, respectively. Theintensity ratio of I₃₃₈/I₃₃₃ was plotted against polymer concentrationto determine the CMC.

Micelle destabilization.

The destabilization of micelles was monitored at two different pHs (5.0and 9.0). For pH 5.0, micelles of block copolymers were formed asdescribed above in isotonic 120 mM ammonium acetate buffer (pH=5.0) at aconcentration of 2 mg/mL. For pH 9.0, samples were prepared as follows.First, the polymers were dissolved in water at 20 mg/mL and then diluted10-fold with 300 mM NaHCO₃ buffer (pH=9.0). Micelles were formed in thesame way as described. For both samples, the size change of micelles andthe change of scattering intensity in time were measured by dynamiclight scattering at 37° C. The results are shown in FIG. 1. This figureshows that under conditions where hydrolysis of the lactic acid sidegroups is minimized (pH=5) the micelles were stable during the time ofthe measurements (60 hours). In contrast, at pH 9 a rapiddestabilization of the micelles is observed.

This destabilization is due to hydrolysis of the lactic acid sidegroups. This hydrolysis is associated with an increase in hydrophilicityof the thermosensitive block. Once the hydrolysis has proceeded to suchan extent that the LCST of this block passes 37° C., the micelles startto dissolve. This happens round 3-4 hours of incubation at 37° C. and pH9.0. Since the hydrolysis of the lactic acid side groups is first orderin hydroxyl ion concentration, a destabilization time of 120-160 hoursat pH 7.4 can be expected.

Table 3 summarizes the characteristics of the different synthesisedblockcopolymers.

TABLE 3 Characteristics of pHPMAmDL-b-PEG block copolymers CMT CMCZ_(ave) Polymers M_(n) ^(a)) M_(w) ^(a)) M_(w)/M_(n) (° C.)^(b))(mg/mL)^(c)) (nm)^(d)) pHPMAmDL(3000)-b-PEG^(e)) 7400 10400 1.41 12.50.15 60 ± 1 pHPMAmDL(6900)-b-PEG^(e)) 11900 23300 1.95 7.5 0.03 51 ± 1pHPMAmDL(13600)-b-PEG^(e)) 15000 32800 2.18 6.0 0.015 53 ± 1 ^(a))M_(n)= number average molar weight; M_(w) = weight average molar weightdetermined by GPC ^(b))Determined by SLS for 10 mg/mL solution in pH 5.0buffer. ^(c))Determined from pyrene excitation spectra at 37° C. in pH5.0 buffer. ^(d))Determined by DLS for 1 mg/mL solution in pH 5.0buffer. ^(e))Number in brackets is M_(n) of HPMAmDL block determined by¹H NMR. M_(n) of PEG is 5000.

EXAMPLE 4 Hydrozels Based on ABA Blockcopolymers of p(HPMAm-dilactate)(A-block) and PEG (b-block)

Hydrogel forming ABA block copolymers of p(HPMAm-dilactate) (A-block)and PEG (b-block) were obtained using the same synthetic strategy asdescribed for the synthesis of AB blockcopolymer (scheme 1). However,instead of the (PEG 5000)₂-ABCPA macroinitiator another type ofmacroinitiator was used. This initiator was synthesized by reaction ofnormal PEG (instead of monomethoxy PEG) with ABCAPA. In detail: 1 mmolof 4,4-azobis-(4-cyanopentanoic acid) (ABCPA), 3 mmol ofN,N′-dicyclohexylcarbodiimide (DCC) and 0.3 mmol4-(dimethyl-amino)pyridinium-4-toluenesulfonate (DPTS) were dissolved inmixture 1:1 of dry tetrahydrofuran (THF) and dichloromethane. Themixture was stirred at room temperature for 10 to 20 minutes. Next, 1mmol poly(ethylene glycol) (PEG, number average molar mass 2000 or 4000)was added. This total mixture was stirred at room temperature for 20 h.Subsequently, the mixture was filtered and the solvent was evaporated.After evaporation, the product was dissolved in water en stirred forcouple of hours and filtered to remove DCU. The filtrate was lyophilizedto yield the PEG-ABCPA. ABA triblockcopolymers of of p(HPMAm-dilactate)(A-block) and PEG (B-block) were obtained as described for the micelleforming AB block copolymers (p(HPMAm-dilactate)-b-PEG block copolymers).

The hydrogel forming properties of the different ABA blockcopolymerswere studied using rheological analysis. In detail: 300 mg of polymerwas dissolved in 700 μl of 100 mM ammonium acetate buffer pH 5 at 0° C.during 24 h. Next, 60 μl of this polymer solution applied to therheometer (AR1000N, Ta instruments) equipped with a Cone/plate geometrywith a radius of 1 cm and an angle of 1°. The temperature was graduallyincreased 0° C. to 50° C. at a ramp of 2° C./min. The rheologicalcharacteristics of the sample were monitored using a frequency of 1 Hzand a strain of 1%. For further experimental details: see De Jong S. J.et al. Novel self-assembled hydrogels by stereocomplex formation inaqueous solution of enatiomeric lactic acid oligomers grafted todextran. Macromolecules 33, 3680-3686, 2000.

Table 4 summarizes the results.

TABLE 4 Rheological properties of ABA blockcopolymers (A =pHPMAmdilactate; B = PEG). Molecular weights (kDa) B block A block G′ at2° C. G″ at 2° C. G′ at 37° C. G″ at 37° C. 4 11 6 40 830 1100 2 10 2 201600 2250 G′ and G″ in Pa · s

EXAMPLE 5

Fast degradable thermosensitive polymeric micelles based onPEG-block-poly(2-hydroxyethyl methacrylamide-lactate) were made based onthe same methodology as described above.

Synthesis HEMAm-oligolactates

The oligolactate esters of 2-hydroxyethyl methacrylamide(HEMAm-oligolactate) were obtained by ring-opening oligomerization ofL-lactide, using HEMAm as the initiator and stannous octoate as acatalyst, essentially as described by Van Dijk et al. [Polymer 38(1997), 6235-6242]. Briefly, L-lactide (33.5 g; 0.233 mol) and HEMAm (20g; 0.155 mol) were stirred at 110° C. until the lactide was molten.4-Methoxyphenol (˜0.1 mol % relative to HEMAm) was added as radicalscavenger. Subsequently, a catalytic amount of SnOct₂ (630 mg; 1 mol %with respect to HEMAm) was added. The resulting mixture was stirred for2 hours and allowed to cool to room temperature. After dissolution ofthe product in 250 ml water-acetonitril (50:50), the HEMAm-oligolactatewas fractionated with preparative chromatography essentially asdescribed by Neradovic et al. [Macromolecules 36 (2003), 7491-7498]. Theidentity of HEMAm mono-, di,- tri-, and tetralactate (furtherabbreviated as HEMAm-Laci, HEMAm-Lac₂, HEMAm-Lac₃ and HEMAm-Lac₄) wasconfirmed by NMR; the purity by HPLC (system as described below).

Degradation kinetics of HEMAm-oligolactates

The degradation kinetic studies of HEMAm-oligolactates were conducted asdescribed by Neradovic et al [Macromolecules; 2003; 36(20); 7491-7498].In brief, a 10 mM solution of HEMAm-oligolactate in DMSO was diluted 10times with 100 mM PBS (pH 7.4) in a glass vial and the pH was adjustedto pH 7.4 with 4 M HCl. The resulting solutions of HEMAm-monolactate,-dilactate, -trilactate and—tetralactate were incubated in a shakingwater bath at 37° C. At regular time intervals samples of 300 μl werewithdrawn and 700 μl of 1 M sodium acetate buffer (pH 3.8) was added toprevent further hydrolysis. The samples were stored at 4° C. prior toHPLC analysis. The hydrolysis of HEMAm-trilactate and—tetralactate wasalso investigated in an acetonitril-PBS pH7.2 mixture (50:50 w/w) oflower dielectric constant to slow down the hydrolysis rate. The HPLCanalysis was carried out on a Waters system (Waters Associates Inc.,Milford, Mass., USA). This consisted of a pump Model 600, anautoinjector Model 717, a variable wavelength absorbance detector Model996 and an analytical reversed phase column LiChrosphere 100 RP-18 (5μm, 125×4 mm i.d.) with an RP-18 guard column (4×4 mm) (Merck) was used.The injection volume was 50 μl and the detection wavelength was 254 nm.After 5 minutes isocratic flow of water/acetonitrile=95:5 (w/w), (eluentA), a gradient was run using eluent A and acetonitrile/water=95:5 (w/w),(eluent B). This gradient was run from 100% A to 100% B in 30 minuteswith a flow rate of 1.0 ml/min. The chromatograms were analyzed withEmpower Software Version 1154 (Waters Associates Inc.). Calibrationcurves were generated for each monomer and its degradation products withfreshly prepared standard solutions in DMSO/PBS pH 7.2 (100 mM)/sodiumacetate buffer pH 3.8 (1 M) (3:27:70) and were at least linear between0.07 and 15 μM.

Results showed that monodisperse HEMAm-oligolactates hydrolyzed to theunsubstituted HEMAm and lactic acid when incubated in pH 7.4 at 37° C.The overall mass balance showed that the amide bond in HEMAm(lactates)was stable under the selected conditions. Concentrations of HEMAm-Lac₁to HEMAm-Lac₄ were determined by the HPLC method described above. Fromthe concentration versus time plots, the half-lives (t_(1/2)) weredetermined. Stock solutions in DMSO were diluted ten times in PBS bufferto solubilize the oligolactates. Therefore, the reported half life timesare expected to be about twice as high in 100% water, as discussed byNeradovic et al. [Macromolecules 36 (2003), 7491-7498].

The half life times of the prepared HEMAm-Lac₁ and HEMAm-Lac₂ are 58 and5.6 hours respectively. At similar conditions (pH 7.5, 10% DMSO) thehalf life of the methacrylate analogue of the HEMAm-lactates i.e.N-(2-hydroxyethyl)methacrylate (HEMA) mono- and dilactate were 31 hoursand 3 hours respectively (Neradovic et al, Macromolecules 36 (2003),7491-7498)

The half life times of HPMAm-monolactate and HPMAm-dilactate arerespectively 87.5 and 15.4 hours. Thus, the HEMAm-lactate offers thepossibility to provide micelles with a shorter half-life than theanalogous HPMAm-lactate, but a higher half-life than the analogousHEMA-lactate. Thereby it is anticipated that the degradation profile ofthe corresponding (co)polymers can be fine-tuned to become suitable as adelivery system for an active compound.

HEMAm derivatives with three and four lactic acid units (HEMAm-Lac₃ andHEMAm-Lac₄) display even faster hydrolysis kinetics than HEMAm-Lac₁₋₂.In order to compare our results with the half life times obtained forthe previously reported HPMAm-oligolactates with 7 and 12 lactate units[Van Nostrum et al, Polymer 45 (2004), 6779-6787], we carried out thedegradation experiments in 50% ACN—PBS 7.2 as well. The half lives ofHPMAm oligolactates (7 and 12 lactate units) under these conditions were3.1 hours, which is only slightly shorter than those of HEMAm-Lac₃ andHEMAm-Lac₄. Thus, an increasing lactate chain length increases thehydrolysis rates of oligolactates until it levels off between 4 and 7lactate units per oligolactate chain. It is envisaged that the higherlactates (in particular the trilactate and the tetralactate polymer) arein particular useful to be used in a blend or copolymer with anotherpolymer according to the invention, in order to modify the half time andthe stability of a delivery system comprising such blend.

Synthesis of (co)-polymers of HEMAm-oligolactates

The (co)polymers were synthesized via free radical polymerization inairtight screw-cap glass vials. AIBN dissolved in 1,4-dioxane (ratio ofmonomers/initiator=100:1 and 150:1 mol/mol) was added to a 200 mg/mlmonomer solution (total volume approximately 1 ml dioxane) Bothhomopolymers (HEMAm, HEMAm-Lac_(n)) and copolymers (made from mixturesof HEMAm-Lac₂ and HEMAm-Lac₄) were synthesized.

A nitrogen flow was led through the solution for at least 10 minutes.The polymerization was conducted at 70° C. for 24 hours while stirringthe solution. Next, the polymers were precipitated by dropwise additionof the solution to an excess of diethyl ether. After centrifugation, theresidue was dried overnight in a vacuum oven at 40° C. ¹H-NMR (DMSO,d₆):δ=7.5 (b, CO—NH—CH₂), 5.5 (b, CH—OH), 5.0 (b, CO—CH(CH3)—O), 4.1 (b,CO—CH—(CH3)-—o.0 (b, CH2—CH2—O), 1.4, (b, CO—CH—CH3), 1.3 (b,HO—CH—CH3),1.0-0.6 (polymer main chain protons).

The HEMAm-Lac₂/HEMAm-Lac₄ comonomer ratio (mol/mol) in the copolymer wasdetermined by 1H NMR from the ratio of the integral of the methynprotons (δ=5.0 ppm) to the alcoholic proton (δ=5.5 ppm). The followingequation was used:

% HEMAm-Lac₄=(I _(5.0) −I _(5.5))/2*100%   (1)

For GPC analysis of the molecular weights and their distribution of thedifferent polymers, a Plgel 3 μm MIXED-D column (Polymer Laboratories)was utilized at a Waters System (Waters Associates Inc., Milford, Mass.,USA) with a differential refractometer Model 410. Poly(ethyleneglycol)of defined molecular weights were used as standards. The eluent was DMFcontaining 10 mM LiCl. The samples were dissolved overnight at aconcentration of 5 mg/ml in the eluent and prior to analysis filteredthrough a 0.45 μm filter. The elution rate was 0.7 ml/min and thetemperature was 40° C. Aqueous GPC was performed on the same system with5 mM ammonium acetate buffer (pH 5.5), PL 8 μm aquagel OH column(Polymer Laboratories) and dextran standards. Peak areas were determinedwith Empower Software Version 1154 (Waters Associates Inc).

The following Table 5 summarizes the results of all homopolymerizations.

TABLE 5 Characteristics of the homopolymers of HEMAm-oligolactates RatioYield M_(w)/ Monomer [M]/[I] (%) M_(w) (GPC) M_(n) CP (° C.) HEMAm 150:192  24000^(a) 3.7 >75 HEMAm-Lac₁ 150:1 71 53000 3.1 >75 HEMAm-Lac₂ 100:181 68000 3.0 21.7 HEMAm-Lac₃   75:1^(b) 83 24000 3.3 <0 HEMAm-Lac₄ 100:176 57700 3.0 <0 ^(a)Insoluble fraction present ^(b)Twice as much AIBNadded because the DP3 monomer contained still some radical scavengerhydroquinone after purification (preparative HPLC)

HEMAm was almost quantitatively converted. The DMF solution for GPCanalysis however was slightly cloudy and the filtration through 0.45 μmfilter was difficult. The product did however fully dissolve in waterand was therefore analyzed by aqueous GPC. This analysis gave amonomodal distribution with an average molecular weight of 194000 g/moland a polydispersity of 22. The pHEMAm-oligolactates were obtained in aconstant high yield (around 80%).

The thermosensitive properties of the polymers were investigated bystatic light scattering. To prevent hydrolysis, a pH 5 buffer was used.pHEMAm-Lac₃ and pHEMAm-Lac₄ did not dissolve after overnight incubationat 0°, suggesting a cloud point below 0° C.

The homopolymers of HEMAm and its monolactate derivative did not showany scattering up to 75° C. The homopolymer of pHEMAm-Lac₂ displayed itsCP at 21.7° C.

The copolymers of HEMAm-Lac₂ and HEMAm-Lac₄ were synthesized withmonomer to AIBN ratio of 100:1. Table 6 summarizes theircharacteristics.

The yields and molecular weights were comparable with the homopolymers.The copolymer composition corresponds with the feed ratio. The CPbehavior of these copolymers (FIG. 7) showed that the amount ofhydrophobic HEMAm-Lac₄ incorporated linearly influenced the CP. Fromthis curve, it was predicted that a copolymer with 22% HEMAm-Lac₄ ormore would not dissolve at 0°. This was experimentally confirmed (Table6).

TABLE 6 Characteristics of copolymers HEMAm-Lac₂/HEMAm-Lac₄ HEMAm-Lac₂/HEMAm- % HEMAm- Lac₄ feed Lac₄ Mw M_(w)/ CP ratio Yield (%)incorporated^(a) (GPC) M_(n) (° C.) 94%-6%  79 8 71000 3.0 14.3 etc88%-12% 76 11 62280 2.85 9.5 85%-15% 88 15 69000 2.48 6.9 82%-18% 77 1868310 2.98 5 76%-24% 76 23 60820 2.76 <0 ^(a)The amount of DP4incorporated in the polymer chain is derived from ¹H NMR.

Block Copolymers of PEG and HEMAm-oligolactates

Block copolymers with HEMAm-Lac_(n) as thermosensitive block and PEG ashydrophilic block were prepared via the macroinitiator route asdescribed by Neradovic et al. [Macromolecules, 2001, 34; 7589-7591].Poly(ethyleneglycol) (PEG)₅₀₀₀ was chosen to be the hydrophilic part ofthe blockcopolymer as this polymer favor longer circulation time ofnanoparticles drug carriers and lower uptake by the RES.

In brief, block copolymers were prepared by radical polymerization usingPEG₂-ABCPA as initiator (ratio of monomer/initiator=150:1 mol/mol). Theconcentration of starting material was 300 mg/ml in acetonitrile inairtight glass vials. A nitrogen flow was led through the solution forat least 10 minutes.

The polymerization was conducted at 70° C. for 24 hours. Next, bydropwise addition of the solution to an excess of diethyl ether, thepolymers were precipitated. After centrifugation, the residue was driedovernight in a vacuum oven at 40° C.

¹H-NMR (DMSO,d₆) (see FIG. 2): δ=7.5 (b, CO—NH—CH2), 5.5 (b, CH—OH), 5.0(b, CO—CH(CH3)-O), 4.1 (b, CO—CH—(CH3)-OH), 4.0 (b, CH2—CH2—O), 3.6 (b,PEG methylene protons, O—CH2—CH2), 1.4, (b, CO—CH—CH3), 1.3(b,HO—CH—CH3), 1.0-0.6 (pHEMAm-Lac_(n) main chain protons).

The number average molecular weight (Mn) of the thermosensitive blockwas determined by ¹H-NMR as follows (in the situation of copolymers, anaverage molecular weight of the monomers M was used):

M _(n=) M _(ave)(HEMAm-Lac_(n))×I _(HEMAm-Lacn)/(I _(PEG)/454)   (2)

I_(HEMAm-Lacn) is the value of the integral of the hydroxyl proton ofthe HEMAm-Lac_(n) (H_(oh) δ=5.5 ppm); I_(PEG) is the value of theintegral of the PEG protons and is divided by the average number ofprotons per one PEG₅₀₀₀ chain (=454).

A block copolymer of PEG and HEMAm-Lac₂ as well as block copolymers withtwenty percent HEMAm-Lac₄ and eighty percent HEMAm-Lac₂ with varyingmonomer to initiator ratios were synthesized. The latter polymerscontained HEMAm-Lac₄ to obtain a polymer with a CP just above 0° C.Table 7 summarizes the characteristics of the obtained blockcopolymers.

TABLE 7 Characteristics of block copolymers PEG-b-(HEMAm-oligolactate)M_(n) % HEMAm Micelle Block Ratio HEMAm- Yield M_(w) M_(w)/ block CMTCMC size Micelle copolymer monomer:initiator Lac₄ incorporated^(a) (%)(GPC) M_(n) (NMR) (° C.)^(b) (mg/L) (ZAve)^(b) PD^(b) PEG-HEMAm- 150:1 —69 49000 2.3 9800 20 n.d.^(e) 124 0.1 Lac₂ etc etc PEG- 150:1 21 8535870 3.1 10600 5.9 0.08 70 0.08 (HEMAm-Lac₂/ HEMAm- Lac₄₎ PEG- 100:1 2095 50000 2.1 25100 78 0.2 (HEMAm-Lac₂/ HEMAm- Lac₄₎ PEG-  50:1 20 8230100 1.9 12000 68 0.1 (HEMAm-Lac₂/ HEMAm- Lac₄₎ ^(a)The amount ofHEMAm-Lac₄ incorporated in the polymer chain is derived from ¹H NMR.^(b)2 mg/ml solution

¹H NMR was used to calculate the number average molecular weights of thethermosensitive block. These were significant lower than the GPCresults.

However, the GPC was calibrated with narrow poly(ethyleneglycol)standards and the Mn is therefore not the absolute molecular weight ofthe polymer. The block copolymer PEG-b-(80% HEMAm-Lac₂-20% HEMAm-Lac₄)has a cloud point of 5.9° C., which is slightly higher than CP of thecopolymer of 82% HEMAm-Lac₂-18% HEMAm-Lac₄ (table 6, 5.0° C.). From thisresult it is concluded that a PEG block slightly increases the CP.

Formation and Characterization of PEG-HEMAm-Lac_(n) Micelles

Micelles were formed via the quick heating procedure of aqueous polymersolutions as described in example 3. The particle size and particle sizedistributions are displayed in Table 7. The incorporation of 20%HEMAm-Lac₄ in the thermosensitive block caused a significant decrease inparticle size. This is found to be relatively independent of the lengthof the thermosensitive block. The presence of longer hydrophobic lactateside chains increases the hydrophobic interactions and creates a morecompact micellar core.

The morphology of the micelle was studied with CryoTEM. FIG. 8 shows arepresentative microphotograph and shows the spherical shape of themicelles as well as their narrow particle size distribution.

The critical micelle concentration (cmc) was determined with pyrene as afluorescent probe [see example 3]. The cmc was determined from the plotof the intensity ratio I₃₃₈/I₃₃₃ as a function of the concentration ofblock copolymer (FIG. 9). For the block copolymer PEG-b-(80%HEMA-Lac₂-20% HEMAm-Lac₄), the cmc was determined to be 0.08 mg/ml,which is low enough for systemic administration in vivo. The particlesizes of micelles prepared from polymer solutions at variousconcentrations above the cmc (0.2-20 mg/ml) are shown in FIG. 10.

Relative large and polydisperse micelles are formed at concentrationsbelow 0.5 mg/ml which is close to the cmc. In the concentration range0.5-10 mg/ml, the particle size were relatively small (70 nm) with a lowpolydispersity. 2 mg/ml polymer solutions were used for furthermeasurements as this gave the lowest PD.

pH Dependent Stability of the Micelles

The PEG-b-pHPMAm-dilactate micelles (see example 3) dissolved afterapproximately one week incubation at physiological conditions (aqueousbuffer pH 7.4, 37° C.). The stability of the micelles ofPEG-b-pHEMAm-lac₂ was followed by DLS measurements during incubation inbuffer pH 5 at 37° C. to slow down hydrolysis. Under these conditions,the micellar particle size gradually increased in time (FIG. 11).

As opposed to PEG-b-HEMAm-Lac₂, incorporation of 20% HEMAm-Lac₄increased the hydrophobicity of the thermosensitive block which resultednot only a smaller particle size (Table 7) but also a higher stabilityof the micelles at pH 5 (FIG. 12). For PEG-b-(80% HEMAm-Lac₂-20%HEMAm-Lac₄) at pH 5, a constant particle size was observed for at least18 hours. At pH 7.4 and 7° C., the particle size hardly changed duringthe first three hours, followed by a swelling phase until 8 hours. Afterthat period, the micelles started to dissolve as seen by the measuredscattering intensity which dropped to zero.

CONCLUSION

Thermosensitive (block co) polymers of HEMAm-oligolactates weresynthesized in high yields by free radical polymerization. It ispossible to accurately tailor the cloud point by adjusting the copolymercomposition of the poly(HEMAm-oligolactates). The increase inhydrophobicity of the thermosensitive block (poly(HEMAm-Lac₂))influenced not only the CP but also the micellar particle size andstability. Twenty percent of HEMAm-Lac₄ was sufficient to increase thehydrophobicity sufficiently to produce highly stable micelles. Animportant issue determining the effectiveness of a micellar drug carrieris the ability to control the time over which drug release takes place,which can be done by a (micellar) drug release system according to theinvention This is advantageous over nondegradable micellar systems asdescribed in the prior art (e.g. PEG-poly(glutamic acid) [Kataoka JContr Release 2005, p 223]. Herein drug release is only mediated bydiffusion, which is a slow process and difficult to control. Thethermosensitive polymeric micelles described here have the advantageover nondegradable micelles or liposomes by their ability to destabilizeafter an induction period that can be tailored by selecting the buildingblock of the polymer quantitatively and/or qualitatively. For instancethe HEMAm-lactate polymer is capable of providing a micellar system thatis stable for approximately 3 hours and thereby controlling the releaseof encapsulated drugs. Furthermore the degradation products are expectedto be bioresorbable, i.e. degradable with elimination from the humanbody. After destabilization of the micelles, it is contemplated that theremaining polymers (Mw<50000) will usually not exhibit toxicity causedby long-term accumulation because it will be excreted by glomerularfiltration [Delgado C, Francis G E, Fisher D 1992, The uses andproperties of PEG-linked proteins. Crit Rev Ther Carrier Syst 9:249-304]. The unique profile of micelle destabilization may beadvantageous for in vivo use because the observed induction period isjust long enough to allow accumulation of the micelles at the site ofe.g. a tumor.

1. A temperature sensitive polymer having a lower critical solutiontemperature that changes during incubation in an aqueous solution ormedium, which polymer is a homo or interpolymer of a hydrophobicallymodified hydroxyalkyl(meth)acrylamide.
 2. The polymer of claim 1,wherein the polymer comprises a hydrophobic group which is bound to thehydroxyalkyl (meth)acrylamide by a hydrolysable bond.
 3. The polymer ofclaim 2, wherein the hydrophobic group is alkyl, aryl, lactic acid orlactic acid oligomers.
 4. The polymer of claim 3, wherein alkyl isselected from the group consisting of methyl, ethyl, propyl, butyl,pentyl and hexyl.
 5. The polymer of claim 1, which polymer is a homo orinterpolymer of an (N-(2-hydroxyalkyl) (meth)acrylamide lactate).
 6. Thepolymer of claim 5, which polymer is selected from the group consistingof homopolymers and interpolymers of (N-2-hydroxyethyl) methacrylamidelactates) and (N-(2-hydroxyethyl) acrylamide lactates).
 7. The polymerof claim 1, wherein the polymer comprises at least one componentselected from monolactates, dilactates, trilactates and tetralactates.and dilactate groups.
 8. The polymer of claim 1, wherein the polymer isa copolymer of (a) at least one hydroxyalkyl (meth)acrylamide(lactate)n, wherein n represents the number of lactate units, n being atleast 3, (b) at least one hydroxyalkyl (meth)acrylamide (lactate)_(n),wherein n is 0, 1 or
 2. 9. (canceled)
 10. The polymer of claim 1, havinga lower critical solution temperature before incubation below human bodytemperature and a different lower critical solution temperature afterincubation above human body temperature.
 11. A controlled release systemcomprising the temperature sensitive polymer of claim 1 and an activeingredient.
 12. The controlled release system of claim 11, wherein thepolymer is in the form of a polymeric micelle in which a hydrophilicblock is present which hydrophilic block comprises a polyalkyleneglycol.13. The controlled release system of claim 11, wherein the system is inthe form of a hydrogel.
 14. The controlled release system of claim 13,wherein the hydrogel is an ABA block copolymer, wherein block A is atemperature sensitive polymer of claim 1 and B is a hydrophilic polymer.15. A targeting drug composition, comprising a drug and particles of thecontrolled release system of claim
 11. 16. The targeting drugcomposition of claim 15, which further comprises a homing device.